Welcome to our dedicated page for Trendlines Group news (Ticker: TRNLY), a resource for investors and traders seeking the latest updates and insights on Trendlines Group stock.
The Trendlines Group Ltd. (OTCQX: TRNLY) appears frequently in news through announcements from its agrifood and medtech portfolio companies. These updates highlight how Trendlines-backed ventures progress from early-stage innovation to regulatory milestones, clinical studies, and commercial launches. Because Trendlines invests in innovation in agrifood and medtech, its news flow is closely tied to developments in crop protection, sustainable agricultural inputs, medical devices, and women’s health technologies.
Readers following TRNLY news can expect coverage of funding rounds and strategic investments involving portfolio companies such as IBI Ag, Escala Medical, Arcuro Medical, Limaca Medical, ElastiMed, Vensica Medical, and EcoPhage. Announcements often describe capital raises that support product development, clinical trials, and international expansion, with The Trendlines Group cited as a portfolio investor, founding partner, or incubator sponsor.
News items also report regulatory achievements and market entry milestones. Examples include FDA 510(k) clearance for Arcuro Medical’s SuperBall-RC system, FDA clearance and CMS Transitional Pass-Through payment for Limaca’s Precision-GI endoscopic biopsy device, and FDA approval and commercial launch of Escala’s women’s health device in the United States. For agrifood companies like EcoPhage and IBI Ag, news emphasizes the development of phage-based bactericides and antibody-based bioinsecticides aimed at sustainable crop protection.
In addition, Trendlines-related news may cover board appointments, strategic partnerships, and geographic expansion, such as new distribution agreements, preparations for European or Asian market entry, and collaborations with global agribusiness and healthcare partners. Investors and observers who want to track how The Trendlines Group’s portfolio evolves can use this news feed as a centralized view of financing events, regulatory progress, and commercialization steps across its agrifood and medtech holdings.
Arcuro Medical has announced a significant milestone, surpassing 4,000 surgical cases worldwide and 1,000 cases in the U.S. with its SuperBall™ Meniscal Repair System. The current version, launched in 2022 with line extensions in 2023, addresses a full range of meniscus tear patterns. CEO Jamal Rushdy expressed excitement about the achievement and future growth prospects.
Dr. Philip Davidson, Arcuro's Medical Director, highlighted the system's unique tensioning mechanism, which provides superior strength and reduced complications compared to other devices. Arcuro has recently made key hires in the U.S., including Jamal Rushdy as CEO and Nick Tonno as Sales Director, to focus on commercial growth. The company plans to provide updates at upcoming industry events in Las Vegas.
Dasyo, a pioneer in noninvasive medical aesthetics technologies, has appointed Domenic (Dom) Serafino as Executive Board Chair. Serafino brings extensive industry experience, having co-founded and led Venus Concept Inc. to over $100 million in annual revenues. He was also instrumental in Syneron Medical Corp's successful IPO. Dasyo, funded by the Israel Innovation Authority and The Trendlines Group (SGX: 42T) (OTCQX: TRNLY), is developing a groundbreaking non-surgical breast lift product using proprietary technology for noninvasive directional skin tightening. This appointment is expected to significantly enhance Dasyo's strategic direction and growth potential in the aesthetics medical device sector.
Ceretrieve announced successful results of its multicenter, single-arm study for its aspiration catheter, aimed at treating acute ischemic stroke (AIS) caused by large vessel occlusion (LVO).
The study involved 20 patients and achieved 100% Complete/Near-Complete Perfusion with the Gen 2 device, far exceeding the 30%-40% rate of current gold-standard devices.
Ceretrieve's device allows single-pass clot removal and full blood flow restoration, ensuring high safety by minimizing the risk of clot fragments moving further into the brain.
The technology demonstrated superior performance compared to existing devices, highlighting its potential to significantly improve post-stroke patient outcomes.
Limaca Medical announced the successful completion of 24 cases using its Precision-GI™ endoscopic ultrasound guided motorized fine needle biopsy (EUS-mFNB) device on May 15, 2024. The device, used in both pancreatic and liver biopsies, showed significant tissue acquisition capabilities. Six cases involved the pancreas and eighteen the liver. Two-thirds of the cases were completed with a single needle pass, achieving top-grade biopsy samples in 21 out of 24 cases. The Precision-GI™ device, designed to obtain biopsies for definitive diagnoses of gastrointestinal cancers, has received FDA Clearance and Breakthrough Device Designation. Dr. Carlos Robles-Medranda, who led the study, praised the device for its efficiency and quality of biopsy tissue obtained.
ZygoFix, a Trendlines portfolio company, has received FDA clearance for its zLOCK Lumbar Facet Fixation System, revolutionizing spinal fusion surgery. The system, backed by strong clinical evidence, offers a minimally invasive procedure with long-term pain reduction benefits. With CE certification and successful clinical utilization, ZygoFix is poised to make a significant impact in the US market.
Arcuro Medical appointed Jamal Rushdy, a seasoned MedTech industry veteran, as its new CEO. Rushdy brings over 28 years of experience in orthopedics and sports medicine. The company aims to enhance patient care with their SuperBall™ technology for meniscus repair. Lee Ranon, the co-founder, transitions to the COO role. The board expresses confidence in Rushdy's leadership for the company's growth.
Summary not available.
liberDi Ltd., a portfolio company of The Trendlines Group, has received FDA clearance for its Digital Dialysis Clinic, allowing patients to perform home dialysis independently with physician monitoring. This advancement aims to improve the quality of life for dialysis patients, who often spend significant time in clinics. The system has demonstrated safety and effectiveness in clinical studies involving 42 subjects and is positioned to disrupt traditional dialysis methods. The technology leverages telemedicine for enhanced patient care.
The Trendlines Group Ltd. (OTCQX: TRNLY) has established a new company, Celleste Bio, aimed at producing high-value cocoa ingredients through cell culture methods. This innovation reduces dependency on cocoa tree cultivation and addresses sustainability challenges associated with traditional cocoa farming. Co-investors include Mondelēz International and Barrel Ventures. Celleste's technology ensures consistent cocoa yields, unaffected by climate. By utilizing naturally occurring cocoa cells, the company aligns with growing consumer demand for environmentally friendly products.
The Bayer Trendlines Ag Innovation Fund has established TierraSpec, a company focused on remote measurement and validation of carbon sequestration in agricultural soil. Utilizing over 30 years of research from Tel Aviv University, TierraSpec aims to provide cost-effective technology for carbon credit issuance and soil health monitoring. This innovation addresses the limited eligibility of agricultural projects for carbon credits, currently at only 1-2%. With a US$10 million investment from Bayer, the initiative supports sustainable agricultural practices and effective carbon reporting.